OMNIAMED
- Biotech or pharma, therapeutic R&D
OmniaMed Inc. is a pioneering biotech company advancing next-generation drug and gene delivery platforms.
Our proprietary NSDC (NO Scavenger Drug Conjugate) platform enables targeted delivery of therapeutics to inflammatory disease sites, offering enhanced efficacy and reduced systemic toxicity—particularly for acute severe ulcerative colitis (ASUC).
In parallel, our POLED (Polymer Library for Enhanced Delivery) platform harnesses polymer-based nanoparticles for mRNA and siRNA delivery, with organ-selective targeting capabilities and long-term gene expression. Through open innovation, strategic partnerships, and licensing, OmniaMed is setting a new paradigm in treating diseases by modulating nitric oxide and enabling precision RNA therapies.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}